Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus cisplatin induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma
ChiCTR2100046393Phase 2Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Treatment failure survival rate. Started May 2021; status: recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100046393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046393.